Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bolt Biotherapeutics, Inc. BOLT

Healthcare  —  Biotechnology
3.58 (0.01) (0.28%) as of 25 Sep
Market cap
$6.9M
P/E
0.0×
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bolt Biotherapeutics, Inc. (BOLT) Business Profile

Updated before January 2025

Company Overview

Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biotechnology company dedicated to developing innovative immuno-oncology therapies. Founded in 2015 and headquartered in Redwood City, California, BOLT was established with the mission of leveraging the power of the immune system to combat cancer. The company was co-founded by Dr. Edgar Engleman, a renowned immunologist, whose groundbreaking research laid the foundation for BOLT’s proprietary technology. The company went public in February 2021, trading on the NASDAQ under the ticker symbol BOLT.

BOLT is led by a team of seasoned professionals with extensive experience in biotechnology and pharmaceuticals. The leadership team includes Randall Schatzman, Ph.D., who serves as the Chief Executive Officer, and Brian O’Callaghan, the Chief Financial Officer. Together, they guide the company’s strategic direction and oversee its research and development efforts.

Core Business Segments

BOLT’s core business revolves around the development of immuno-oncology therapies, with a focus on its proprietary Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs). These therapies are designed to harness the body’s immune system to target and destroy cancer cells. The company’s major product categories include:

Boltbody™ ISAC Platform

  • BOLT-22: A lead candidate in clinical trials targeting HER2-positive cancers. This therapy combines tumor-targeting antibodies with immune-stimulating agents to activate the immune system.
  • BOLT-45: Another promising candidate aimed at addressing solid tumors by engaging innate and adaptive immune responses.

Preclinical Pipeline

  • Next-Generation ISACs: BOLT is actively working on expanding its pipeline with next-generation ISACs targeting a broader range of cancers.
  • Combination Therapies: The company is exploring the potential of combining ISACs with other immunotherapies to enhance efficacy.

Research and Development Services

BOLT also collaborates with academic institutions and pharmaceutical companies to advance the understanding of immuno-oncology and develop novel therapeutic approaches.

Business Model

BOLT operates on a research-driven business model, focusing on the discovery, development, and commercialization of innovative cancer therapies. The company generates revenue through:

  • Collaborations and Partnerships: BOLT partners with leading pharmaceutical companies to co-develop therapies and share resources.
  • Licensing Agreements: The company licenses its proprietary technology to other biotech firms, generating milestone payments and royalties.
  • Clinical Development: BOLT invests heavily in clinical trials to bring its therapies to market, with the goal of achieving regulatory approval and commercial success.

Strategic Direction

BOLT’s strategic direction is centered on expanding its pipeline, advancing its clinical programs, and exploring new therapeutic areas. Key initiatives include:

  • Pipeline Expansion: Developing next-generation ISACs and exploring new targets for cancer immunotherapy.
  • Global Reach: Establishing partnerships with international pharmaceutical companies to expand its market presence.
  • Sustainability Goals: Incorporating environmentally sustainable practices in its research and manufacturing processes.
  • Innovation: Investing in cutting-edge technologies to enhance the efficacy and safety of its therapies.

Competitive Landscape

BOLT operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Genentech: A leader in oncology therapies with a strong focus on antibody-based treatments.
  • Bristol-Myers Squibb: Known for its immuno-oncology portfolio, including checkpoint inhibitors.
  • AstraZeneca: A major player in cancer immunotherapy with a diverse pipeline.
  • Smaller Biotech Firms: Companies like Iovance Biotherapeutics and Adaptimmune Therapeutics also compete in the immuno-oncology space.

Risk Factors

BOLT faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The company’s therapies must undergo rigorous clinical trials and regulatory reviews, which can be time-consuming and costly.
  • Market Dependence: BOLT’s success is heavily reliant on the commercial viability of its ISAC platform.
  • Supply Chain Disruptions: The company depends on third-party suppliers for raw materials and manufacturing, making it vulnerable to disruptions.
  • Competition: Intense competition in the biotech sector could limit BOLT’s market share.
  • Financial Risks: As a clinical-stage company, BOLT relies on external funding and may face challenges in securing additional capital.

Recent Developments

BOLT has made significant progress in advancing its clinical programs and expanding its pipeline. Recent developments include:

  • Clinical Trial Updates: Positive interim results from Phase 1/2 trials of BOLT-22, demonstrating safety and efficacy in HER2-positive cancers.
  • New Partnerships: Collaboration with a leading pharmaceutical company to co-develop next-generation ISACs.
  • Technological Innovations: Introduction of a new platform technology to enhance the targeting capabilities of its therapies.
  • Global Developments: The COVID-19 pandemic posed challenges to clinical trial timelines, but BOLT successfully adapted by implementing remote monitoring and virtual site visits.

Investment Considerations

Investors considering BOLT should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Proprietary ISAC platform with significant potential in cancer immunotherapy.
  • Experienced Leadership: A seasoned management team with a proven track record in biotechnology.
  • Strong Pipeline: A robust pipeline of clinical and preclinical candidates targeting high-value oncology markets.
  • Collaborative Approach: Strategic partnerships with leading pharmaceutical companies.

Risks

  • Clinical and Regulatory Uncertainty: The success of BOLT’s therapies depends on positive clinical trial outcomes and regulatory approvals.
  • Financial Dependence: As a clinical-stage company, BOLT relies on external funding and may face challenges in raising capital.
  • Market Competition: Intense competition from established players and emerging biotech firms.
  • Operational Risks: Potential supply chain disruptions and manufacturing challenges.

Conclusion

Bolt Biotherapeutics, Inc. is at the forefront of cancer immunotherapy, leveraging its proprietary ISAC platform to develop innovative therapies. With a strong pipeline, experienced leadership, and strategic partnerships, BOLT is well-positioned to make a significant impact in the oncology market. However, the company faces challenges such as regulatory hurdles, financial dependence, and market competition. Overall, BOLT’s innovative approach and commitment to advancing cancer treatment make it a compelling player in the biotechnology sector, with significant growth potential in the years ahead.